Adherium Ltd – New Independent Data on Adherium Smartinhaler™ Clinical Outcomes Shows Increased Adherence and Reduction in Severe Attacks

/in ,

30 September 2015. Link here. ..Three independent studies support the positive impact of Smartinhaler™ Platform in paediatric asthma. ..144% increase in adherence and 37% reduction in oral steroids indicating reduced severe exacerbations. ..Data disclosed at prestigious European Respiratory Congress in Amsterdam. ..Adds to data on Adherium’s SmartInhaler published in Lancet Respiratory Medicine Adherium Limited (ASX: ADR), […]

Read more

Nexvet Receives FY2015 Cash Refund of $3.2 Million

/in ,

DUBLIN, Ireland, Sept. 29, 2015 (GLOBE NEWSWIRE). Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced receipt of US$3.2 million in cash under the Australian Federal Government’s Research and Development (R&D) Tax Incentive program. This program provides a 45 percent refundable tax offset for qualifying R&D in Australia, where Nexvet conducts its drug discovery […]

Read more

Rex Bionics Plc notes two legal cases awarding insurance funding for wheelchair user access to the REX robotic walking device

/in ,

18 September, link here. Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, notes two recent legal settlements — awarding funding for the purchase of a REX robot and funding for Robot-Assisted Physiotherapy with REX. These developments help to establish an important principle – that individuals […]

Read more

Nexvet Secures Biomanufacturing Facility and Receives IDA Ireland Support

/in ,

DUBLIN, Ireland, Sept. 16, 2015 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced it has secured a dedicated biologics manufacturing facility in Tullamore, Ireland. The transaction is supported by the Irish Government’s Department of Jobs, Enterprise & Innovation through IDA Ireland, their foreign investment agency. BioNua Limited, a wholly-owned subsidiary […]

Read more

Adherium digital health lists on ASX at 10% premium

/in ,

Media Release Monsoon Communications Digital health company’s technology improves adherence and patient health in chronic respiratory disease $35m maximum oversubscribed by Aust & international institutions & retail investors 26 August 2015: Digital health company Adherium Limited (ASX:ADR) listed on the Australian Securities Exchange today opening at 55 cents per share, a 10 per cent premium to […]

Read more

AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT

/in ,

San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 18, 2015 Link here. AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of […]

Read more

Adherium $35m ASX IPO to expand sales of digital health technology to improve medication adherence

/in ,

–          Digital health company’s technology proven to improve adherence and patient health in chronic respiratory disease –          $25.85m in signed commitments, AstraZeneca US$3m cornerstone investment; led by Bell Potter Securities –          First-in-class 10 year Supply and Development Agreement with AstraZeneca –          Technology has been used in 40 projects, across 29 countries, with 32 publications referencing Smartinhaler 5 August 2015 […]

Read more

AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT

/in ,

Company Announces One-for-Fifty Reverse Stock Split Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015 San Diego and Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, August 04, 2015 –Linkhere. AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today […]

Read more

Sea Dragon – Market Update

/in ,

28 July 2015. Link here. SeaDragon Limited (NZX:SEA) today releases an update to the market detailing the company’s progress towards completing the Omega-3 production plant. The update also includes an overview of; • Key products • Customers • The rationale for investment in SeaDragon • The use of proceeds • Financial forecasts • Sustainability statement For […]

Read more

Adherium & AstraZeneca Partner to Improve the Lives of Individuals with Respiratory Disease

/in ,

23 July 2015. Link here. First-in-class collaboration combining digital health with class leading inhaled medications Long term international supply agreement targeted at AstraZeneca’s patient support programs Adherium’s Smartinhaler proven to substantially improve medication adherence and health outcomes in adults and children New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader […]

Read more